Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

Study’s first results presented at the international “Collaborative Workshop – Ivermectin against Covid-19” held on December 15, 16 and 17 at the initiative of MedinCell

No side effects observed with the first two doses in the study, which includes a total of three doses

A first long-acting injectable formulation is ready to enter regulatory development